Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer.
cellular proliferation
colorectal cancer
immunohistochemistry
mesothelin
prognosis
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
20
06
2019
accepted:
21
11
2019
entrez:
21
3
2020
pubmed:
21
3
2020
medline:
21
3
2020
Statut:
ppublish
Résumé
Mesothelin (MSLN) is a glycophosphatidylinositol (GPI)-linked cell surface protein that is highly expressed in several types of malignant tumor, including malignant pleural mesothelioma, ovarian cancer and pancreatic adenocarcinoma. Recently, a comprehensive immunohistochemical study using MN-1 monoclonal antibody identified a significant number of colorectal tumors in which MSLN was expressed. However, the clinicopathological profiles and survival of patients with MSLN-positive colorectal cancer have not been fully analyzed. In the current study, the expression of MSLN in 270 primary and 44 metastatic colorectal tumors was immunohistochemically analyzed to determine the clinical usefulness of MSLN immunohistochemistry and to identify potential candidates for future anti-MSLN therapy.
Identifiants
pubmed: 32194667
doi: 10.3892/ol.2020.11290
pii: OL-0-0-11290
pmc: PMC7039175
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1741-1750Informations de copyright
Copyright: © Inoue et al.
Références
Clin Cancer Res. 2012 May 1;18(9):2478-89
pubmed: 22371455
Oncotarget. 2015 May 10;6(13):11694-703
pubmed: 26028668
Am J Surg Pathol. 2003 Feb;27(2):150-8
pubmed: 12548160
Am J Surg Pathol. 1992 Mar;16(3):259-68
pubmed: 1599018
Oncogene. 2011 Feb 10;30(6):714-23
pubmed: 20972463
Clin Cancer Res. 2005 Aug 15;11(16):5840-6
pubmed: 16115924
Br J Cancer. 2012 Jun 26;107(1):137-42
pubmed: 22644300
Carcinogenesis. 2011 Jul;32(7):1013-24
pubmed: 21515913
Biomark Res. 2019 Aug 23;7:18
pubmed: 31463062
Virchows Arch. 2019 Mar;474(3):297-307
pubmed: 30603773
Mol Cell Biol. 2000 Apr;20(8):2902-6
pubmed: 10733593
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40
pubmed: 8552591
J Pathol Clin Res. 2017 Oct 07;3(4):268-278
pubmed: 29085667
Oncotarget. 2015 Sep 29;6(29):28257-68
pubmed: 26318045
Breast Cancer Res Treat. 2014 Oct;147(3):675-84
pubmed: 25193277
Am J Clin Pathol. 2005 Dec;124(6):838-45
pubmed: 16416732
Biochem J. 2009 Dec 10;424(3):449-58
pubmed: 19747165
Cancer Res. 2013 Dec 15;73(24):7313-23
pubmed: 24165159
Oncotarget. 2017 Apr 18;8(16):26744-26754
pubmed: 28460459
Cancer Immunol Res. 2017 Nov;5(11):1046-1055
pubmed: 29038297
Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):243-7
pubmed: 16082249
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Clin Cancer Res. 2014 Feb 15;20(4):1020-8
pubmed: 24334761
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31
pubmed: 16467095
Am J Surg Pathol. 2003 Nov;27(11):1418-28
pubmed: 14576474
Medicine (Baltimore). 2019 Jun;98(26):e16207
pubmed: 31261569
Lung Cancer. 2016 Nov;101:104-110
pubmed: 27794397
J Gastroenterol. 2014 Jan;49(1):81-92
pubmed: 23512344
Cancer Discov. 2018 Dec;8(12):1548-1565
pubmed: 30322867